Impaired thymopoiesis occurring during the thymic involution of tumor-bearing mice is associated with a down-regulation of the antiapoptotic proteins Bcl-XL and A1
- PMID: 19082511
Impaired thymopoiesis occurring during the thymic involution of tumor-bearing mice is associated with a down-regulation of the antiapoptotic proteins Bcl-XL and A1
Abstract
The thymus is a central lymphoid organ in which T lymphocytes undergo differentiation and maturation without the need for antigenic stimulation. Apoptosis (programmed cell death), plays a critical role in shaping the T cell repertoire, deleting unproductive as well as potentially autoreactive T cells. Thymic atrophy has been observed in several model systems, including aging, graft-vs-host-disease and tumor development. However, the mechanisms involved in this phenomenon remain to be completely elucidated. We have previously shown that the progressive growth of D1-DMBA-3 mammary tumor leads to extreme thymic atrophy in the host. This thymic involution is associated with an early block in T cell maturation at the triple negative stage of differentiation. In the present study we have used our murine mammary tumor model to further analyze the specific T cell subpopulations present in the thymus of tumor-bearing animals as well as to characterize the alterations of the apoptotic process present during the impaired thymopoiesis associated to this thymic involution. Flow cytometric analysis revealed a moderate increase in the percentages of single positive CD4+ and CD8+ cells within the CD3 negative population in the thymuses of tumor-bearing mice. Moreover, we observed a prolonged increase in apoptosis among thymocytes from tumor-bearing mice compared with thymocytes from normal mice during tumor development. Lastly, we found a major decrease of Bcl-XL and A1, two crucial anti-apoptotic Bcl-2 family members that are developmentally regulated in T cells. Together, our data suggest that the severe thymic involution seen in mammary tumor bearers is due to an arrest in at least two steps of T cell differentiation and a down-regulation of important molecules that control programmed cell death.
Similar articles
-
Thymic involution and thymocyte phenotypic alterations induced by murine mammary adenocarcinomas.J Immunol. 1989 Dec 15;143(12):4300-7. J Immunol. 1989. PMID: 2592775
-
Role of thymic stromal cell dysfunction in the thymic involution of mammary tumor-bearing mice.Anticancer Res. 2002 Jan-Feb;22(1A):91-6. Anticancer Res. 2002. PMID: 12017339
-
bcl-2 proto-oncogene expression during human T cell development. Evidence for biphasic regulation.J Immunol. 1993 Jul 1;151(1):83-91. J Immunol. 1993. PMID: 8326141
-
Apoptosis in normal and neoplastic mammary gland development.Microsc Res Tech. 2001 Jan 15;52(2):171-81. doi: 10.1002/1097-0029(20010115)52:2<171::AID-JEMT1003>3.0.CO;2-T. Microsc Res Tech. 2001. PMID: 11169865 Review.
-
The role of apoptosis in the development and function of T lymphocytes.Cell Res. 2005 Oct;15(10):749-69. doi: 10.1038/sj.cr.7290345. Cell Res. 2005. PMID: 16246265 Review.
Cited by
-
Prolonged survival in mice with advanced tumors treated with syngeneic or allogeneic intra-bone marrow-bone marrow transplantation plus fetal thymus transplantation.Cancer Immunol Immunother. 2010 Jul;59(7):1121-30. doi: 10.1007/s00262-010-0840-2. Epub 2010 Mar 13. Cancer Immunol Immunother. 2010. PMID: 20229083 Free PMC article.
-
Downregulation of interleukin-7 and hepatocyte growth factor in the thymic microenvironment is associated with thymus involution in tumor-bearing mice.Cancer Immunol Immunother. 2009 Dec;58(12):2059-72. doi: 10.1007/s00262-009-0714-7. Epub 2009 May 7. Cancer Immunol Immunother. 2009. PMID: 19421751 Free PMC article.
-
Pre-clinical toxicity assessment of tumor-targeted interleukin-12 low-intensity electrogenetherapy.Cancer Gene Ther. 2011 Apr;18(4):265-74. doi: 10.1038/cgt.2010.77. Epub 2011 Jan 14. Cancer Gene Ther. 2011. PMID: 21233859 Free PMC article.
-
Insights into thymic involution in tumor-bearing mice.Immunol Res. 2013 Dec;57(1-3):106-14. doi: 10.1007/s12026-013-8446-3. Immunol Res. 2013. PMID: 24198066 Review.
-
Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy.Oncotarget. 2016 Dec 20;7(51):84965-84980. doi: 10.18632/oncotarget.13087. Oncotarget. 2016. PMID: 27821803 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials